Jan Królak

Dr. Jan Królak

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EMEliza Matuszewska-Mach
Eliza Matuszewska-Mach
PBPaulina Borysewicz
Paulina Borysewicz
JKJan Królak
Jan Królak
MJMagdalena Juzwa-Sobieraj
Magdalena Juzwa-Sobieraj
JMJan Matysiak
Jan Matysiak
Honeybee products (HBPs), including honey, bee pollen, bee bread, royal jelly, propolis, beeswax, and bee brood, are increasingly used in food, nutraceutical, and cosmetic contexts. Because of their natural origin, HBPs can provoke allergic reactions ranging from localised dermatitis to life-threatening, systemic anaphylaxis. As the use of bee products for health purposes grows in apitherapy (a branch of alternative medicine), raising public awareness of their potential risks is essential. This narrative review synthesises the clinical manifestations of HBP allergy, culprit allergens present in each product, immunological mechanisms, diagnostic approaches, at-risk populations, and knowledge gaps. The analysis of the available literature suggests that, although relatively rarely, HPB may trigger allergic reactions, including anaphylactic shock. The sensitisation mechanism may be associated with both primary sensitisation and cross-reactivity and can be classified into type I (IgE-mediated) and type IV (T-cell-mediated). However, bee bread appears less allergenic than other HBPs, potentially due to lactic fermentation that can degrade allergenic proteins. Severe reactions following intake of bee bread have not been reported to date. Management of HBP allergic reactions centres on avoiding the products, educating about the risks, and providing more precise product labelling, specifying the allergen content. Individuals with atopy and beekeepers are at heightened risk of developing anaphylaxis; therefore, they should be particularly aware of the potential dangerous consequences of HPB use. Further research is needed to clarify the mechanisms of HBP allergies and improve safety for all users.

24 March 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Paweł UruskiPaweł Uruski
Paweł Uruski
JMJustyna Mikula-Pietrasik
Justyna Mikula-Pietrasik
ENEryk Naumowicz
Eryk Naumowicz
KKKamila Kaźmierczak
Kamila Kaźmierczak
AGAndrey Gaiday
Andrey Gaiday
KKKrzysztof Książek
Krzysztof Książek
The mechanisms and clinical significance of the cellular senescence of tumor cells are a matter of ongoing debate. Recently, the triggers and molecular events underlying spontaneous, replicative senescence of primary epithelial ovarian cancer cells were characterized. In this study, we reanalyzed tumors obtained from ovarian cancer patients with respect to the expression of the senescence biomarkers SA-β-Gal and γ-H2A.X and the proliferative antigen Ki67. The results showed that the tumors displayed strong heterogeneity with respect to the expression of analyzed markers. The expression of SA-β-Gal and γ-H2A.X in the oldest patients (61–85 y.o.) was significantly higher than in the younger age groups. Conversely, the area of Ki67-positive cancer cells was greater in younger individuals. At the same time, there was a positive correlation between SA-β-Gal expression and calendar age in FIGO III–IV and malignant ascites-positive patients. The γ-H2A.X positively correlated with age in the whole group, FIGO III–IV, and ascites-positive patients. Ki67 levels correlated negatively with the age of patients among those same groups. Collectively, our study indicated that organismal aging may determine the development of the senescence phenotype in ovarian tumors, particularly in patients with advanced disease and those accumulating malignant ascites.

28 November 2025 in Artery Research
Verified
Journal Article
Open access
PDF file
SWStanislaw Wasiliew
Stanislaw Wasiliew
DLDawid Lipski
Dawid Lipski
LSLukasz Stryczynski
Lukasz Stryczynski
ARArtur Radziemski
Artur Radziemski
JKJan Królak
Jan Królak
Paweł UruskiPaweł Uruski
Paweł Uruski
Background: Resistant hypertension affects 10–15% of treated patients and remains a therapeutic challenge. Eplerenone is recommended when spironolactone is ineffective or poorly tolerated. Central blood pressure (BP) correlates more strongly with cardiovascular complications than peripheral BP, and pulse wave velocity (PWV) reflects arterial stiffness, a key factor in hypertension-related morbidity. While spironolactone is well-established for resistant hypertension, data on eplerenone’s efficacy and safety for this indication is limited. Interleukin-6 (IL-6) is involved in resistant hypertension and the pressor response to angiotensin II, with elevated levels suggesting its role in aldosterone regulation and potential as a therapeutic target. This study aimed to evaluate the efficacy of eplerenone (25–50 mg/day) on central aortic BP, PWV, office BP, ambulatory BP monitoring (ABPM), and IL-6 levels after four weeks. Twenty-seven patients with confirmed resistant hypertension received eplerenone for four weeks. Office BP, ABPM, central aortic BP, PWV, and safety markers (potassium, creatinine) were measured. IL-6 levels were assessed at baseline and post-treatment. Results: Significant reductions were observed in office BP (SBP: −13.93 mmHg, DBP: −7.64 mmHg), aortic BP (SBP: −13.42 mmHg, DBP: −7.94 mmHg), 24 h-ABPM (SBP: −7 mmHg, DBP: −3 mmHg), and PWV (− 1.52 m/s). Doubling the eplerenone dose from 25 mg to 50 mg daily reduces aortic systolic blood pressure threefold. IL-6 levels also decreased significantly ( p = 0.023). Conclusions: Eplerenone effectively reduces central and peripheral BP, arterial stiffness, and IL-6 levels, potentially lowering cardiovascular risk in resistant hypertension.